Patent ID: 8097423
Filing Date: 2012-01-17
Classification: C12Q,G01N,Y10T

Abstract:
1. A method of predicting resistance to endocrine therapy in a breast cancer patient with an ER-positive breast tumor, comprising: (a) obtaining a breast tumor tissue sample from said ER-positive breast cancer patient; (b) determining immunologically whether said sample is MN/CA IX-positive, wherein MN/CA IX positivity is indicated by any conventionally detectable MN/CA IX-specific immunohistochemical staining of cells in said sample; and (c) correlating a finding of combined ER-positivity in said tumor and MN/CA IX-positivity in said sample with a greater probability of resistance to said endocrine therapy for said ER-positive breast cancer patient than if said tumor were ER-positive and said sample were MN/CA IX-negative.